Literature DB >> 22550944

Pharmacotherapy to control behavioral symptoms in children with autism.

Carolyn A Doyle1, Christopher J McDougle.   

Abstract

INTRODUCTION: Autistic disorder, Asperger's disorder, and pervasive developmental disorder not otherwise specified (PDD-NOS) are pervasive developmental disorders (PDDs) frequently associated with behavioral symptoms that may require pharmacotherapy to manage. AREAS COVERED: Behavioral symptoms in children with autism include interfering repetitive behaviors, irritability, and hyperactivity and inattention, among others. The psychotropic medications examined in this review include: serotonin reuptake inhibitors, typical and atypical antipsychotics, medications used to treat attention-deficit/hyperactivity disorder, naltrexone, buspirone, divalproex sodium, lamotrigine, levetiracetam, memantine, mirtazapine, riluzole, pioglitazone, and topiramate. EXPERT OPINION: For the treatment of interfering repetitive behaviors, serotonin reuptake inhibitors demonstrate less efficacy and are more poorly tolerated in children with autism compared to adults. Antipsychotics are the most efficacious drugs for the treatment of irritability in children with autism and other PDDs. For the treatment of hyperactivity and inattention, psychostimulants demonstrate some benefit. However, they are overall less efficacious and cause more side effects in children with PDDs compared to typically developing children with attention-deficit/hyperactivity disorder. Results from double-blind, placebo-controlled trials of these agents and others for the treatment of the behavioral symptom domains described above will be discussed in this review.

Entities:  

Mesh:

Year:  2012        PMID: 22550944     DOI: 10.1517/14656566.2012.674110

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  21 in total

Review 1.  Advances in nonhuman primate models of autism: Integrating neuroscience and behavior.

Authors:  M D Bauman; C M Schumann
Journal:  Exp Neurol       Date:  2017-08-01       Impact factor: 5.330

2.  Lurasidone treatment in a child with autism spectrum disorder with irritability and aggression.

Authors:  Presenters Hun Millard; Jennifer L McLaren; Discussant Barbara J Coffey
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-08       Impact factor: 2.576

3.  Aripiprazole decreases irritability in 12 out of 14 youth with autism spectrum disorders.

Authors:  Ann Maloney; Eric O Mick; Jean Frazier
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-05-14       Impact factor: 2.576

4.  Prevalence of Psychotropic Medicine Use in Australian Children with Autism Spectrum Disorder: A Drug Utilization Study Based on Children Enrolled in the Longitudinal Study of Australian Children.

Authors:  Lotte Rasmussen; Nicole Pratt; Elizabeth Roughead; Anna Moffat
Journal:  J Autism Dev Disord       Date:  2019-01

5.  Is 'bench-to-bedside' realistic for autism? An integrative neuroscience approach.

Authors:  Melissa D Bauman; Cynthia M Schumann
Journal:  Neuropsychiatry (London)       Date:  2013-04

6.  Disruption of social approach by MK-801, amphetamine, and fluoxetine in adolescent C57BL/6J mice.

Authors:  Sheryl S Moy; Randal J Nonneman; Geoffrey O Shafer; Viktoriya D Nikolova; Natallia V Riddick; Kara L Agster; Lorinda K Baker; Darin J Knapp
Journal:  Neurotoxicol Teratol       Date:  2012-08-07       Impact factor: 3.763

Review 7.  Mesenchymal stem cells in treating autism: Novel insights.

Authors:  Dario Siniscalco; James Jeffrey Bradstreet; Nataliia Sych; Nicola Antonucci
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

8.  Pitolisant in an Adolescent with Prader-Willi Syndrome.

Authors:  Stephanie Pennington; Danielle Stutzman; Elise Sannar
Journal:  J Pediatr Pharmacol Ther       Date:  2021-05-19

9.  Marble burying and nestlet shredding as tests of repetitive, compulsive-like behaviors in mice.

Authors:  Mariana Angoa-Pérez; Michael J Kane; Denise I Briggs; Dina M Francescutti; Donald M Kuhn
Journal:  J Vis Exp       Date:  2013-12-24       Impact factor: 1.355

Review 10.  Pharmacotherapy for the core symptoms in autistic disorder: current status of the research.

Authors:  Cristan Farmer; Audrey Thurm; Paul Grant
Journal:  Drugs       Date:  2013-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.